| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
355,150,000 |
| Market
Cap: |
2.50(B) |
| Last
Volume: |
17,273,575 |
Avg
Vol: |
17,225,593 |
| 52
Week Range: |
$5.72 - $10.61 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 400 MIDCAP |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bausch Health Companies develops, manufactures and markets, primarily in the therapeutic areas of eye-health, gastroenterology and dermatology, a range of: pharmaceuticals, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Co.'s portfolio of products falls into four operating and reportable segments: Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,313 |
6,533 |
13,261 |
14,828 |
| Total Sell Value |
$61,867 |
$63,491 |
$119,170 |
$133,715 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
2 |
4 |
7 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gordon Joseph F |
Pres&Co-Head Bausch&Lomb/Intl |
• – – |
2022-03-01 |
4 |
AS |
$23.82 |
$150,971 |
D/D |
(6,338) |
112,179 |
|
-64% |
|
| Papa Joseph C |
Chairman & CEO |
• • – |
2022-02-28 |
4 |
D |
$24.06 |
$123,067 |
D/D |
(5,115) |
1,107,795 |
|
- |
|
| Papa Joseph C |
Chairman & CEO |
• • – |
2022-02-27 |
4 |
D |
$24.35 |
$2,765,113 |
D/D |
(113,557) |
1,112,910 |
|
- |
|
| Papa Joseph C |
Chairman & CEO |
• • – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
208,231 |
1,239,650 |
|
- |
|
| Eldessouky Sam |
EVP & Chief Financial Officer |
• – – |
2022-02-27 |
4 |
D |
$24.35 |
$97,887 |
D/D |
(4,020) |
120,697 |
|
- |
|
| Eldessouky Sam |
EVP & Chief Financial Officer |
• – – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,674 |
125,531 |
|
- |
|
| Ackermann Christina |
EVP AND GENERAL COUNSEL |
• – – |
2022-02-27 |
4 |
D |
$24.35 |
$390,282 |
D/D |
(16,028) |
170,005 |
|
- |
|
| Ackermann Christina |
EVP AND GENERAL COUNSEL |
• – – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,292 |
186,033 |
|
- |
|
| Spurr Robert |
U.S. President-Pharma Business |
• • – |
2022-02-27 |
4 |
D |
$24.35 |
$177,682 |
D/D |
(7,297) |
66,989 |
|
- |
|
| Spurr Robert |
U.S. President-Pharma Business |
• • – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,615 |
75,914 |
|
- |
|
| Gordon Joseph F |
Pres&Co-Head Bausch&Lomb/Intl |
• – – |
2022-02-27 |
4 |
D |
$24.35 |
$193,558 |
D/D |
(7,949) |
118,517 |
|
- |
|
| Gordon Joseph F |
Pres&Co-Head Bausch&Lomb/Intl |
• – – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,350 |
127,988 |
|
- |
|
| Munsch Frederick |
SVP, Controller and CAO |
• – – |
2022-02-27 |
4 |
D |
$24.35 |
$40,226 |
D/D |
(1,652) |
23,790 |
|
- |
|
| Munsch Frederick |
SVP, Controller and CAO |
• – – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,330 |
25,748 |
|
- |
|
| Appio Thomas |
CEO, Pharma Business |
• – – |
2022-02-27 |
4 |
D |
$24.35 |
$272,330 |
D/D |
(11,184) |
328,141 |
|
- |
|
| Appio Thomas |
CEO, Pharma Business |
• – – |
2022-02-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,292 |
341,517 |
|
- |
|
| Papa Joseph C |
Chairman & CEO |
• • – |
2022-02-26 |
4 |
D |
$24.35 |
$321,006 |
D/D |
(13,183) |
1,126,116 |
|
- |
|
| Eldessouky Sam |
EVP & Chief Financial Officer |
• – – |
2022-02-26 |
4 |
D |
$24.35 |
$19,821 |
D/D |
(814) |
121,615 |
|
- |
|
| Spurr Robert |
U.S. President-Pharma Business |
• • – |
2022-02-26 |
4 |
D |
$24.35 |
$39,642 |
D/D |
(1,628) |
68,640 |
|
- |
|
| Gordon Joseph F |
Pres&Co-Head Bausch&Lomb/Intl |
• – – |
2022-02-26 |
4 |
D |
$24.35 |
$37,061 |
D/D |
(1,522) |
120,233 |
|
- |
|
| Munsch Frederick |
SVP, Controller and CAO |
• – – |
2022-02-26 |
4 |
D |
$24.35 |
$7,451 |
D/D |
(306) |
24,124 |
|
- |
|
| Appio Thomas |
CEO, Pharma Business |
• – – |
2022-02-26 |
4 |
D |
$24.35 |
$53,375 |
D/D |
(2,192) |
330,543 |
|
- |
|
| Spurr Robert |
U.S. President-Pharma Business |
• • – |
2022-02-15 |
4 |
AS |
$25.02 |
$81,340 |
D/D |
(3,251) |
60,299 |
|
-66% |
|
| Spurr Robert |
U.S. President-Pharma Business |
• – – |
2022-01-18 |
4 |
AS |
$26.63 |
$86,574 |
D/D |
(3,251) |
63,550 |
|
-63% |
|
| Robertson Russel C |
Director |
• • – |
2021-12-31 |
4 |
A |
$27.61 |
$38,102 |
D/D |
1,380 |
126,585 |
|
- |
|
1049 Records found
|
|
Page 6 of 42 |
|
|
0.38 (5.13%) 
